Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) just reported positive results from its phase 1 study using soquelitinib [CPI-818] for the treatment of patients with atopic dermatitis [AD]. Being that ...
Corvus Pharmaceuticals (NASDAQ:CRVS) lost ~34% in the premarket on Wednesday after the company announced early results from a Phase 1 trial for its lead asset, soquelitinib, in patients with ...
Soquelitinib reduced EASI scores by 55.9% at 28 days and 69.1% at 58 days versus 27.0% and 19.1% for placebo. At day 58, 90% of soquelitinib patients achieved EASI 50, with no significant safety ...
BURLINGAME, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced interim ...
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The trial will enroll 64 ...
Today, a brief rundown of news involving Tessera Therapeutics and Corvus Pharmaceuticals, as well as updates from Sarepta Therapeutics, Cara Therapeutics and Johnson & Johnson that you may have missed ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback